Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial aims to clarify the effect of hyaluronic acid on skin conditions.
In this study, investigators will evaluate the skin condition before and after the intervention. The groups to be compared are two different doses of hyaluronic and a placebo.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hyaluronic Acid 150 mg | Active Comparator | Take 150 mg/day of hyaluronic acid. |
|
| Hyaluronic Acid 100 mg | Active Comparator | Take 100 mg/day of hyaluronic acid. |
|
| Placebo | Placebo Comparator | Take 0 mg/day of hyaluronic acid. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hyaluronic acid 75 mg/capsule | Dietary Supplement | Take 2 capsules per day at any time. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline skin viscoelasticity | In skin viscoelasticity measurement using Cutometer MPA580®, skin displacement is measured by applying negative pressure to the skin through the opening of the probe and releasing the negative pressure. The higher the value, the greater the viscoelasticity. Measurement part:Measure the center of the left face, connecting the bottom of the earlobe and the edge of the lip. Accepted value:Measure the same place 5 times, and use the average of 3 measurements with the highest and lowest value data removed based on the R2 value. Analysis target value:R0, R2, R5, R7 | Week0, 2, 4, 8 and week 4 after the end of intake |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline skin moisture content | Skin moisture content is evaluated by using a Corneometer CM825®t | Week0, 2, 4, 8 and week 4 after the end of intake |
| Change from baseline trans-epidermal water transpiration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Atsushi Nakajima, MD | Ueno Asagao Clinic | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ueno Asagao Clinic | Taito-ku | Tokyo | 110-0015 | Japan |
Data sharing will be discussed among the research affiliates after the study is completed.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006820 | Hyaluronic Acid |
| ID | Term |
|---|---|
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hyaluronic acid 50 mg/capsule | Dietary Supplement | Take 2 capsules per day at any time. |
|
| Placebo | Dietary Supplement | Take 2 capsules per day at any time. |
|
Trans-epidermal water transpiration is evaluated by using Tewameter TM300®
| Week0, 2, 4, 8 and week 4 after the end of intake |
| Change from baseline VISIA image | Analyze the following items are measured and simply by putting face into VISIA Evolution. Measurement points:Photograph the left face Analysis target value:Blemishes, Wrinkles, Texture. Pores, Ultraviolet Blemishes, Brown Blemishes, Red Areas, Porphyrin.Higher numbers for these items indicate more advanced aging. Gloss is measured by VISIA-CR. | week 0, 2, 4, 8 and week 4 after the end of intake |
| Change from baseline face visual evaluation | Face visual evaluation is measured by the dermatologist. Evaluation items:Cutaneous carpus, cutaneous groove, comprehensive evaluation Evaluation site:Evaluation centered on the left face, connecting the lower earlobe and the edge of the lip Evaluation method:Perform visual judgment using DermLite DL100 (J Hewitt Co., Ltd.) and microscope (KH-1300/HXG-2016Z/HIROX). There are 5 levels of evaluation, and judgment is made using the following criteria. -2 (Poor), -1 (Slightly Poor), 0 (Normal), 1 (Somewhat Good), 2 (Good) Time Frame: Week 0, 2, 4, 8 and week 4 after the end of intake | Week0, 2, 4, 8 and week 4 after the end of intake |